Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.
2.

Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered.

Roose SP, Rutherford BR, Wall MM, Thase ME.

Br J Psychiatry. 2016 May;208(5):416-20. doi: 10.1192/bjp.bp.115.163261.

3.

Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.

Bushnell GA, Stürmer T, Swanson SA, White A, Azrael D, Pate V, Miller M.

Psychiatr Serv. 2016 Mar;67(3):302-9. doi: 10.1176/appi.ps.201500088. Epub 2015 Nov 16.

4.

Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).

Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB.

Drug Saf. 2014 Nov;37(11):971-80. doi: 10.1007/s40264-014-0225-0.

5.
6.

Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.

Lu CY, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penfold RB, Simon G, Ahmedani BK, Clarke G, Hunkeler EM, Waitzfelder B, Owen-Smith A, Raebel MA, Rossom R, Coleman KJ, Copeland LA, Soumerai SB.

BMJ. 2014 Jun 18;348:g3596. doi: 10.1136/bmj.g3596.

7.

Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome.

Rutherford BR, Tandler J, Brown PJ, Sneed JR, Roose SP.

Am J Geriatr Psychiatry. 2014 Dec;22(12):1452-61. doi: 10.1016/j.jagp.2013.09.003. Epub 2013 Nov 5.

8.

Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.

Rutherford BR, Cooper TM, Persaud A, Brown PJ, Sneed JR, Roose SP.

J Clin Psychiatry. 2013 Jul;74(7):703-15. doi: 10.4088/JCP.12r08267.

9.

A critical review of methods to evaluate the impact of FDA regulatory actions.

Briesacher BA, Soumerai SB, Zhang F, Toh S, Andrade SE, Wagner JL, Shoaibi A, Gurwitz JH.

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):986-94. doi: 10.1002/pds.3480. Epub 2013 Jul 12. Review.

10.

A model of placebo response in antidepressant clinical trials.

Rutherford BR, Roose SP.

Am J Psychiatry. 2013 Jul;170(7):723-33. doi: 10.1176/appi.ajp.2012.12040474. Review.

11.

Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids.

Salinas GD, Robinson CO, Abdolrasulnia M.

J Pain Res. 2012;5:363-9. doi: 10.2147/JPR.S35798. Epub 2012 Oct 5.

12.

Is there a gap between recommended and 'real world' practice in the management of depression in young people? A medical file audit of practice.

Hetrick SE, Thompson A, Yuen K, Finch S, Parker AG.

BMC Health Serv Res. 2012 Jun 27;12:178. doi: 10.1186/1472-6963-12-178.

13.

Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC.

Med Care. 2012 Jun;50(6):466-78. doi: 10.1097/MLR.0b013e318245a160. Review.

14.

Genome-wide association study of antidepressant treatment-emergent suicidal ideation.

Menke A, Domschke K, Czamara D, Klengel T, Hennings J, Lucae S, Baune BT, Arolt V, Müller-Myhsok B, Holsboer F, Binder EB.

Neuropsychopharmacology. 2012 Feb;37(3):797-807. doi: 10.1038/npp.2011.257. Epub 2011 Oct 26.

15.

Practical suicide-risk management for the busy primary care physician.

McDowell AK, Lineberry TW, Bostwick JM.

Mayo Clin Proc. 2011 Aug;86(8):792-800. doi: 10.4065/mcp.2011.0076. Epub 2011 Jun 27. Review.

16.

Randomized trial of depression follow-up care by online messaging.

Simon GE, Ralston JD, Savarino J, Pabiniak C, Wentzel C, Operskalski BH.

J Gen Intern Med. 2011 Jul;26(7):698-704. doi: 10.1007/s11606-011-1679-8. Epub 2011 Mar 8.

17.

Who receives outpatient monitoring during high-risk depression treatment periods?

Kales HC, Kim HM, Austin KL, Valenstein M.

J Am Geriatr Soc. 2010 May;58(5):908-13. doi: 10.1111/j.1532-5415.2010.02810.x. Epub 2010 Apr 14.

18.
19.

Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns?

Busch SH, Frank RG, Leslie DL, Martin A, Rosenheck RA, Martin EG, Barry CL.

Psychiatr Serv. 2010 Jan;61(1):11-6. doi: 10.1176/appi.ps.61.1.11.

20.

News coverage of FDA warnings on pediatric antidepressant use and suicidality.

Barry CL, Busch SH.

Pediatrics. 2010 Jan;125(1):88-95. doi: 10.1542/peds.2009-0792. Epub 2009 Dec 7.

Supplemental Content

Support Center